Overview

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Status:
Recruiting
Trial end date:
2022-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
Phase:
Phase 1
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Nivolumab